News

IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

FDA Project Team supports the company’s proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment schedule,…

1 year ago

Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List

Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial ExecutionCORAL GABLES, Fla., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Catalyst…

1 year ago

Recludix Pharma to Participate in Two Investor Conferences in December

SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in discovery of inhibitors of challenging targets for…

1 year ago

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of…

1 year ago

Vittoria Biotherapeutics Announces Oral and Poster Presentations at the 66th American Society of Hematology (ASH) Annual Meeting

PHILADELPHIA, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, a clinical-stage immunotherapy company specializing in the development of innovative cell therapies…

1 year ago

BetterLife Obtains Favourable Cardiac Safety Data for BETR-001

VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF…

1 year ago

Annovis to Host Year-End Investor Webcast on December 11, 2024

MALVERN, Pa., Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform…

1 year ago

Neural Therapeutics Undertakes Multiple Initiatives to Defer and Eliminate a Significant Portion of Financial Obligations

Toronto, Ontario--(Newsfile Corp. - November 25, 2024) - Neural Therapeutics Inc. ("Neural" or the "Company"), an ethnobotanical drug discovery company…

1 year ago

Psyched Wellness Announces Appointment of New Director and Resignation of a Director

Toronto, Ontario--(Newsfile Corp. - November 25, 2024) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or…

1 year ago

Delivra Health Brands and its Leading Brands Dream Water (R) and LivRelief(TM) Report Financial Results for First Quarter of Fiscal 2025

Vancouver, British Columbia--(Newsfile Corp. - November 25, 2024) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) ("Delivra Health" or…

1 year ago